title: Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.
abstract: OBJECTIVE
  Cardiac resynchronization therapy (CRT) implantable cardioverter defibrillators (ICDs) deliver high burden ventricular pacing to heart failure patients, which has a significant effect on battery longevity. The aim of this study was to investigate whether battery longevity is comparable for CRT-ICDs from different manufacturers in a contemporary cohort of patients.
  
  
  RESULTS
  All the CRT-ICDs implanted at our institution from 1 January 2008 to 31 December 2010 were included in this analysis. Baseline demographic and clinical data were collected on all patients using the electronic medical record. Detailed device information was collected on all patients from scanned device printouts obtained during routine follow-up. The primary endpoint was device replacement for battery reaching the elective replacement indicator (ERI). A total of 646 patients (age 69 ± 13 years), implanted with CRT-ICDs (Boston Scientific 173, Medtronic 416, and St Jude Medical 57) were included in this analysis. During 2.7 ± 1.5 years follow-up, 113 (17%) devices had reached ERI (Boston scientific 4%, Medtronic 25%, and St Jude Medical 7%, P < 0.001). The 4-year survival rate of device battery was significantly worse for Medtronic devices compared with devices from other manufacturers (94% for Boston scientific, 67% for Medtronic, and 92% for St Jude Medical, P < 0.001). The difference in battery longevity by manufacturer was independent of pacing burden, lead parameters, and burden of ICD therapy.
  
  
  CONCLUSIONS
  There are significant discrepancies in CRT-ICD battery longevity by manufacturer. These data have important implications on clinical practice and patient outcomes.
authors.affiliation: Cardiovascular Electrophysiology, Heart and Vascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, PUH B535, Pittsburgh, PA 15213, USA.
authors.forename: Mian Bilal
authors.initials: MB
authors.lastname: Alam
authors.forename: Muhammad Bilal
authors.initials: MB
authors.lastname: Munir
authors.forename: Rohit
authors.initials: R
authors.lastname: Rattan
authors.forename: Susan
authors.initials: S
authors.lastname: Flanigan
authors.forename: Evan
authors.initials: E
authors.lastname: Adelstein
authors.forename: Sandeep
authors.initials: S
authors.lastname: Jain
authors.forename: Samir
authors.initials: S
authors.lastname: Saba
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058406:Cardiac Resynchronization Therapy / Q000009:adverse effects; D058409:Cardiac Resynchronization Therapy Devices; D017147:Defibrillators, Implantable; D020878:Device Removal; D004554:Electric Countershock / Q000009:adverse effects / Q000295:instrumentation*; D011211:Electric Power Supplies; D004867:Equipment Design; D004868:Equipment Failure; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010414:Pennsylvania; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
keywords: Battery longevity; Cardiac resynchronization therapy; Defibrillator; Manufacturer